Research Article
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
Published Online:1 Dec 2010https://doi.org/10.2217/pgs.10.128
Abstract
Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6. In our current study, we tested whether genetic polymorphisms in CYP1A2 are associated with the treatment efficacy and side effects of paroxetine. Materials & methods: A total of 241 MDD patients who had taken paroxetine continually for 8 weeks were recruited, and their steady state paroxetine concentrations were measured at weeks 2, 4 and 8. The genotypes of these patients were then assessed for the presence of nine SNPs, which were selected from either the HapMap Chinese ethnic group, the literature report or through their functional role in the CYP1A2 gene. Results: The allele types for SNPs rs4646425 (permutation p = 0.03), rs2472304 (permutation p = 0.01) and rs2470890 (permutation p = 0.004) demonstrated significant associations with paroxetine treatment remission at week 8. Response rates in the Hamilton Rating Scale for Depression (HAM-D) and for The Hamilton Rating Scale for Anxiety (HAM-A) were significantly associated with the SNPs rs4646425 (p = 0.0126 and 0.0088 for HAM-D and HAM-A, respectively) and rs4646427 (p = 0.0067 and 0.0196 for HAM-D and HAM-A, respectively). The inducible SNP rs762551 had a significant association with paroxetine dose at week 4 (permutation p = 0.012). We did not find an association between these SNPs and the side effects or serum concentrations of paroxetine. Conclusion: Genetic variants in the CYP1A2 region may be indicators of treatment response in MDD patients to paroxetine.
Keywords:
Papers of special note have been highlighted as: ▪ of interest
Bibliography
- 1 Sjoholm L, Lavebratt C, Forsell Y: A multifactorial developmental model for the etiology of major depression in a population-based sample. J. Affect. Disord.113,66–76 (2009).
- 2 Suija K, Kalda R, Maaroos HI: Patients with depressive disorder, their co-morbidity, visiting rate and disability in relation to self-evaluation of physical and mental health: a cross-sectional study in family practice. BMC Fam. Pract.10,38 (2009).
- 3 Chien I, Kuo C, Bih S et al.: The prevalence and incidence of treated major depressive disorder among National Health Insurance enrollees in Taiwan, 1996 to 2003. Can. J. Psychiatry52,28–36 (2007).
- 4 Hansen R, Gaynes B, Thieda P et al.: Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr. Serv.59,1121–1130 (2008).
- 5 Zobel A, Maier W: Pharmacogenetics of antidepressive treatment. Eur. Arch. Psychiatry Clin. Neurosci.260(5),407–417 (2010).
- 6 Laje G, McMahon FJ: The pharmacogenetics of major depression: past, present, and future. Biol. Psychiatry62,1205–1207 (2007).
- 7 Pae CU, Patkar AA: Paroxetine: current status in psychiatry. Expert Rev. Neurother.7,107–120 (2007).
- 8 Jornil J, Jensen KG, Larsen F, Linnet K: Identification of cytochrome p450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab. Dispos.38,376–385 (2010).▪ Describes the metabolic pathway of paroxetine and identifies CYP1A2 as a metabolic enzyme for the drug.
- 9 Kaye CM, Haddock RE, Langley PF et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. Suppl.350,60–75 (1989).
- 10 Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev.58,521–590 (2006).
- 11 Kristoffersen L, Bugge A, Lundanes E, Slordal L: Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection. J. Chromatogr.734,229–246 (1999).
- 12 Haddock RE, Johnson AM, Langley PF et al.: Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand. Suppl.350,24–26 (1989).
- 13 Tang SW, Helmeste D: Paroxetine. Expert Opin. Pharmacother.9,787–794 (2008).
- 14 Andersohn F, Willich SN: Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ340,c783 (2010).
- 15 Hori H, Yoshimura R, Ueda N, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J: A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J. Biol. Psychiatry10,620–622 (2009).
- 16 Ereshefsky L, Jhee S, Grothe D: Antidepressant drug-drug interaction profile update. Drugs R D6,323–336 (2005).
- 17 Laika B, Leucht S, Heres S, Schneider H, Steimer W: Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J.10,20–29 (2010).▪ Demonstrates that the role of CYP1A2*1F influences olanzapine concentration.
- 18 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, The Fourth Edition (Text-Revised). American Psychiatric Publisher, Washington, DC, USA (2000).
- 19 Hamilton M: Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol.6,278–296 (1967).
- 20 Uhr M, Tontsch A, Namendorf C et al.: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron57,203–209 (2008).
- 21 Hamilton M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatr.23,56–62 (1960).
- 22 Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication No. ADM 76-338 (Revised Edition). National Institute of Health, Psychopharmacology Research Branch Publishers, MD, USA, 76–338 (1976).
- 23 Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry7,1115–1119 (2002).
- 24 Ventura J, Liberman RP, Green MF, Shaner A, Mintz J: Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res.79,163–173 (1998).
- 25 Muller MJ, Dragicevic A: Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. J. Affect. Disord.77,65–69 (2003).
- 26 Cohen J: Weighted k: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol. Bull.70,213–220 (1968).
- 27 Cohen J: A coefficient of agreement for nominal scales. Educ. Psychol. Meas.20,37–46 (1960).
- 28 McGahuey CA, Gelenberg AJ, Laukes CA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther.26,25–40 (2000).
- 29 Tiwari AK, Souza RP, Muller DJ: Pharmacogenetics of anxiolytic drugs. J. Neural. Transm.116,667–677 (2009).
- 30 Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther.116,496–526 (2007).
- 31 Yuan HY, Chiou JJ, Tseng WH et al.: FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res.34,W635–W641 (2006).▪ Describes the use of a webpage for searching for the functional role of SNPs.
- 32 Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics21,263–265 (2005).
- 33 Riedel M, Moller HJ, Obermeier M et al.: Response and remission criteria in major depression – a validation of current practice. J. Psychiatr. Res.44(15),1063–1068 (2010).
- 34 Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science296,2225–2229 (2002).
- 35 Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther. Drug Monit.22,143–154 (2000).
- 36 Serretti A, Calati R, Massat I et al.: Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol.24,250–256 (2009).
- 37 Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol.47,445–449 (1999).
- 38 Basile VS, Ozdemir V, Masellis M et al.: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry5,410–417 (2000).
- 39 Tsai MH, Lin KM, Hsiao MC et al.: Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics11,537–546 (2010).
- 40 Takeuchi DT, Chung RC, Lin KM et al.: Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles. Am. J. Psychiatry155,1407–1414 (1998).
- 101 Clinical trial with the US NIH www.clinicaltrial.gov/ct/show/NCT00384020
- 102 HapMap tagSNPs www.hapmap.org/index.html.en
